Back to search

Peptide record

TPDB91276

FLAK50 HB43 Antibacterial Anticancer Antifungal Hemolysis Toxicity standard
13 amino acids
Basic Information
3D PDB MODEL
Drag to rotate. Click a residue or atom to inspect it; the selected residue is highlighted in amber.
TPDB91276
FLAK50 HB43
Antibacterial Anticancer Antifungal Hemolysis Toxicity
Anti-infective peptides Cancer-related peptides Toxicity and safety peptides
AntiBP3 Peptipedia AntiCP 2.0 CancerPPD 2.0 SATPdb iACP-DRLF Antifungipept CAFPdb dbAMP PD_Hemolysis
standard
No
A 13-aa standard natural multi-activity (Antibacterial, Anticancer, Antifungal, and other sources) peptide sequence curated from AntiBP3, Peptipedia, AntiCP 2.0, and other sources, with an available 3D structural model.
C-terminal: Amidation
Sequence
FAKLLAKLAKKLL-NH2
Physicochemical Analysis
C72H129N17O14
RNDCEQGHIMPSTWYV
L
1456.92
11.00
4
0
9
+4
-0.48
0.892
173.08
Mammalian: 1.1 hour Yeast: 3 min E.coli: 2 min
0
0.00
0
Residue Composition
number
3
A
0
R
0
N
0
D
0
C
0
E
0
Q
0
G
0
H
0
I
5
L
4
K
0
M
1
F
0
P
0
S
0
T
0
W
0
Y
0
V
Amino Acid Distribution
A: 3 R: 0 N: 0 D: 0 C: 0 E: 0 Q: 0 G: 0 H: 0 I: 0 L: 5 K: 4 M: 0 F: 1 P: 0 S: 0 T: 0 W: 0 Y: 0 V: 0
Chemical Descriptors
13
C72H129N17O14
1456.92
11.00
+4
-0.48
0.892
Amidation
L
Linear
Free
Anticancer
FLAK peptides Synthetic
Evidence Records 10 records
Evidence 1 Activity

Activity

LD50
LD50 =9 µg/ml
Anticancer
9 µg/mL

Target

Breast Cancer
MCF-7
Breast

Assay & Model

MTT/MTS assay
24-h

Source & Reference

CancerPPD 2.0 SATPdb
CancerPPD2
2005
US_06875744_B2

Other

Source Activity Label Source Definition
Anticancer
CancerPPD 2.0 manually curated experimentally verified anticancer peptide/protein annotation.
Evidence 2 Activity

Activity

LD50
LD50 =9 µg/ml
Anticancer
9 µg/mL

Target

Colon Cancer
SW-480
Colon

Assay & Model

MTT/MTS assay
24-h

Source & Reference

CancerPPD 2.0 SATPdb
CancerPPD2
2005
US_06875744_B2
Evidence 3 Activity

Activity

LD50
LD50 =7 µg/ml
Anticancer
7 µg/mL

Target

Skin Cancer
BMKC
Skin

Assay & Model

MTT/MTS assay
24-h

Source & Reference

CancerPPD 2.0 SATPdb
CancerPPD2
2005
US_06875744_B2
Evidence 4 Activity

Activity

LD50
LD50 =6 µg/ml
Anticancer
6 µg/mL

Target

Lung Cancer
H-1299
Lung

Assay & Model

MTT/MTS assay
24-h

Source & Reference

CancerPPD 2.0 SATPdb
CancerPPD2
2005
US_06875744_B2
Evidence 5 Activity

Activity

LD50
LD50 =12 µg/ml
Anticancer
12 µg/mL

Target

Prostate Cancer
PC-3
Prostate

Assay & Model

MTT/MTS assay
24-h

Source & Reference

CancerPPD 2.0 SATPdb
CancerPPD2
2005
US_06875744_B2
Evidence 6 Activity

Activity

LD50
LD50 =15 µg/ml
Anticancer
15 µg/mL

Target

Cervical Cancer
HeLa
Cervix

Assay & Model

MTT/MTS assay
24-h

Source & Reference

CancerPPD 2.0 SATPdb
CancerPPD2
2005
US_06875744_B2
Evidence 7 Activity

Activity

IC50
IC50 = 12 ± 4 µM
Anticancer
12

Target

Colon Cancer
SW-480
Colon

Assay & Model

AlamarBlue assay
24-h

Source & Reference

CancerPPD 2.0 SATPdb
CancerPPD2
2022
Evidence 8 Activity

Activity

IC50
IC50 = 10 ± 1 µM
Anticancer
10

Target

Colon Cancer
SW-620
Colon

Assay & Model

AlamarBlue assay
24-h

Source & Reference

CancerPPD 2.0 SATPdb
CancerPPD2
2022
Evidence 9 Activity

Activity

IC50
IC50 = 11 ± 1 µM
Anticancer
11

Target

Colon Cancer
HT-29
Colon

Assay & Model

AlamarBlue assay
24-h

Source & Reference

CancerPPD 2.0 SATPdb
CancerPPD2
2022
Evidence 10 Activity

Activity

50% cell viability at 20 µM
Anticancer

Target

Breast Cancer
MDA-MB-231
Breast

Assay & Model

AlamarBlue assay
Not Available

Source & Reference

CancerPPD 2.0 SATPdb
CancerPPD2
2022